Acadia Pharmaceuticals Inc
WKN: 603035 / ISIN: US0042251084Der Zeitpunkt ist günstig für den einstieg
15.03.10 17:49
#77
Tifflor
1,69 + 9% USA
Schaut euch mal den Chart an, sowie die erhöhte Volumenszunahme
16.03.10 14:21
#78
smilli1111
Im Nasdaq
brief schon bei 1,75$
bin ja mal gespannt wie es den rest der woche weitergeht
bin ja mal gespannt wie es den rest der woche weitergeht
10.05.10 22:25
#79
brunneta
Geschäftsjahr 2010
ACADIA reported a net loss of $5.5 million, or $0.14 per common share, for the first quarter of 2010 compared to a net loss of $15.0 million, or $0.40 per common share, for the first quarter of 2009.
At March 31, 2010, ACADIA's cash, cash equivalents, and investment securities totaled $40.6 million compared to $47.1 million at December 31, 2009. ACADIA continues to expect its existing cash resources and anticipated payments from its collaborations will be sufficient to fund its operations through the end of 2011.
"The beginning of 2010 has been an important period for ACADIA as we and our pimavanserin partner, Biovail, have advanced our preparations for clinical trials of pimavanserin in three separate indications with large unmet medical needs," said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. "We have refined the design of our new Phase III trial in Parkinson's disease psychosis and we remain on track to initiate this study mid-year. We also are continuing to plan for Phase III co-therapy trials in schizophrenia and a Phase II feasibility study for Alzheimer's disease psychosis. We believe this broad development program with pimavanserin, coupled with ACADIA's other product candidates in development, positions us with multiple attractive product and commercial opportunities and significant growth potential."
Revenues increased to $2.1 million for the first quarter of 2010 from $374,000 for the first quarter of 2009. This increase was primarily due to $1.4 million in revenues recognized under ACADIA's collaboration with Biovail, which commenced in May 2009, as well as increased revenues from other agreements.
Research and development expenses decreased to $5.8 million for the first quarter of 2010, including $229,000 in stock-based compensation, from $12.6 million for the first quarter of 2009, including $221,000 in stock-based compensation. This decrease was primarily due to $5.3 million in lower external service costs as well as cost savings from ACADIA's restructuring implemented in October 2009. The decrease in external service costs was primarily attributable to lower clinical costs incurred on ACADIA's Phase III program with pimavanserin for Parkinson's disease psychosis.
General and administrative expenses decreased to $1.8 million for the first quarter of 2010, including $252,000 in stock-based compensation, from $3.0 million for the first quarter of 2009, including $354,000 in stock-based compensation. This decrease was primarily due to lower external service costs and cost savings from ACADIA's restructuring.
Conference Call and Webcast Information
ACADIA management will review its first quarter results and development programs via conference call and webcast later today at 5:00 p.m. Eastern Time. The conference call may be accessed by dialing 866-730-5770 for participants in the U.S. or Canada and 857-350-1594 for international callers (reference passcode 42433083). A telephone replay of the conference call may be accessed through May 24, 2010 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 90954803). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there until May 24, 2010.
http://www.finanznachrichten.de/...ter-2010-financial-results-004.htm
At March 31, 2010, ACADIA's cash, cash equivalents, and investment securities totaled $40.6 million compared to $47.1 million at December 31, 2009. ACADIA continues to expect its existing cash resources and anticipated payments from its collaborations will be sufficient to fund its operations through the end of 2011.
"The beginning of 2010 has been an important period for ACADIA as we and our pimavanserin partner, Biovail, have advanced our preparations for clinical trials of pimavanserin in three separate indications with large unmet medical needs," said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. "We have refined the design of our new Phase III trial in Parkinson's disease psychosis and we remain on track to initiate this study mid-year. We also are continuing to plan for Phase III co-therapy trials in schizophrenia and a Phase II feasibility study for Alzheimer's disease psychosis. We believe this broad development program with pimavanserin, coupled with ACADIA's other product candidates in development, positions us with multiple attractive product and commercial opportunities and significant growth potential."
Revenues increased to $2.1 million for the first quarter of 2010 from $374,000 for the first quarter of 2009. This increase was primarily due to $1.4 million in revenues recognized under ACADIA's collaboration with Biovail, which commenced in May 2009, as well as increased revenues from other agreements.
Research and development expenses decreased to $5.8 million for the first quarter of 2010, including $229,000 in stock-based compensation, from $12.6 million for the first quarter of 2009, including $221,000 in stock-based compensation. This decrease was primarily due to $5.3 million in lower external service costs as well as cost savings from ACADIA's restructuring implemented in October 2009. The decrease in external service costs was primarily attributable to lower clinical costs incurred on ACADIA's Phase III program with pimavanserin for Parkinson's disease psychosis.
General and administrative expenses decreased to $1.8 million for the first quarter of 2010, including $252,000 in stock-based compensation, from $3.0 million for the first quarter of 2009, including $354,000 in stock-based compensation. This decrease was primarily due to lower external service costs and cost savings from ACADIA's restructuring.
Conference Call and Webcast Information
ACADIA management will review its first quarter results and development programs via conference call and webcast later today at 5:00 p.m. Eastern Time. The conference call may be accessed by dialing 866-730-5770 for participants in the U.S. or Canada and 857-350-1594 for international callers (reference passcode 42433083). A telephone replay of the conference call may be accessed through May 24, 2010 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 90954803). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there until May 24, 2010.
http://www.finanznachrichten.de/...ter-2010-financial-results-004.htm
02.06.10 15:17
#80
brunneta
June 9, 2010
ACADIA Pharmaceuticals To Present at the Ninth Annual Needham Healthcare Conference on June 9, 2010
http://www.finanznachrichten.de/...-conference-on-june-9-2010-004.htm
http://www.finanznachrichten.de/...-conference-on-june-9-2010-004.htm
18.06.10 07:41
#81
Chalifmann3
Klappts im 2.anlauf ? Wünsche viel glück !
SAN DIEGO (TheStreet) --Acadia Pharmaceuticals'(ACAD) experimental drug pimavanserin failed to reduce psychosis in patients with Parkinson's disease compared to a placebo, according to results from a pivotal phase III study announced Tuesday.
Acadia shares closed Monday at $5.84, close to the stock's 52-week high, but were plunging nearly 70% in premarket trading Tuesday.
Acadia was a $1 stock in early May, bid up by hopeful health care investors seeking a repeat of the stock-ripping study results that catapulted Human Genome Sciences(HGSI) earlier this summer.
The primary goal of the phase III trial was to determine whether treatment with pimavanserin could significantly decrease psychosis -- mainly hallucinations and delusions - that often afflict Parkinson's patients.
Yet on this measure, the drug failed to produce positive results, as measured by the Scale for the Assessment of Positive Symptoms (SAPS). Treatment with pimavanserin at two different dose strengths resulted in mean reductions in SAPS scores of 5.8 points and 6.7 points, but treatment with a placebo resulted in a 5.9-point lowering of the SAPS score.
The difference was not statistically significant, primarily due to larger than expected improvement in placebo-treated patients, the company said.
Pimavanserin didn't exacerbate the motor impairment typically seen in patients with Parkinson's, a key secondary endpoint.
"While we obviously are disappointed with the results of this Phase III study, we continue to believe in the potential of pimavanserin based on our clinical experience to date,"said Uli Hacksell, Acadia's chief executive.
Acadia is conducting a second phase III study of pimavanserin. The drug is being developed in partnership with Canadian drug maker Biovail(BVF).
-- Reported by Adam Feuerstein in Boston
mfg
chali
Acadia shares closed Monday at $5.84, close to the stock's 52-week high, but were plunging nearly 70% in premarket trading Tuesday.
Acadia was a $1 stock in early May, bid up by hopeful health care investors seeking a repeat of the stock-ripping study results that catapulted Human Genome Sciences(HGSI) earlier this summer.
The primary goal of the phase III trial was to determine whether treatment with pimavanserin could significantly decrease psychosis -- mainly hallucinations and delusions - that often afflict Parkinson's patients.
Yet on this measure, the drug failed to produce positive results, as measured by the Scale for the Assessment of Positive Symptoms (SAPS). Treatment with pimavanserin at two different dose strengths resulted in mean reductions in SAPS scores of 5.8 points and 6.7 points, but treatment with a placebo resulted in a 5.9-point lowering of the SAPS score.
The difference was not statistically significant, primarily due to larger than expected improvement in placebo-treated patients, the company said.
Pimavanserin didn't exacerbate the motor impairment typically seen in patients with Parkinson's, a key secondary endpoint.
"While we obviously are disappointed with the results of this Phase III study, we continue to believe in the potential of pimavanserin based on our clinical experience to date,"said Uli Hacksell, Acadia's chief executive.
Acadia is conducting a second phase III study of pimavanserin. The drug is being developed in partnership with Canadian drug maker Biovail(BVF).
-- Reported by Adam Feuerstein in Boston
mfg
chali
03.07.10 20:39
#83
Chalifmann3
....
Haase tomaten auffe augen ? Lies dir doch einfach #81 durch,dann weisst du warum ...
MFG
Chali
MFG
Chali
13.08.10 10:40
#84
brunneta
News Acadia Pharmaceuticals
http://www.mysmartrend.com/news-briefs/news-watch/...er-382-loss-acad
27.10.10 19:22
#85
smilli1111
ziemlich ruhig hier
weiß jemand was neues?
ist jemand da der investiert ist?
ist jemand da der investiert ist?
10.01.11 16:22
#88
brunneta
Aufwärtstrend für Acadia Pharmaceuticals
und preiswerte Aktie
http://www.mysmartrend.com/news-briefs/...ard-momentum-shares-acadia-
Acadia Pharmaceuticals: Stock zu sehen: Bis 40,9%
http://translate.google.de/...ia-pharmaceuticals-stock-watch-409-acad
http://www.mysmartrend.com/news-briefs/...ard-momentum-shares-acadia-
Acadia Pharmaceuticals: Stock zu sehen: Bis 40,9%
http://translate.google.de/...ia-pharmaceuticals-stock-watch-409-acad
25.01.12 19:36
#93
brunneta
Hot Stock Acadia Pharmaceuticals
http://www.mysmartrend.com/news-briefs/...uticals-shares-gain-83-acad
21.03.12 16:29
#95
smilli1111
was meint ihr,
die 2,5$ werden kurzfristig kommen meine ich.
nur für wie lange. zuletzt hatten wir sie nur nen tag
nur für wie lange. zuletzt hatten wir sie nur nen tag
25.09.12 16:41
#96
Leo4Essen
Gemessen an dem Potential und der
Tatsache, dass Acadia ein Produkt für Parkinson-Patienten in der Phase III hat und Ende Novenmber schon Ergebnisse erwartet, ist eine Marktkapitalisierung von 110 Mio Euro ja ein Witz.
- > 1 Million Parkinson Patienten gibt es ind en USA
- jedes Jahr werden 60,000 neue Patienten mit Parkinson diagnostiziert
- da der Wirkstoff auch bei Alkzheimerpatienten eingesetzt werden könnte, wird das marktpotential auf > 1 Milliarde USD geschätzt
Fakt ist: Acadia ist noch billig zu haben, das Potential ist sehr groß und die bisherigen Studien geben Anlass zur Hoffnung, dass die jetzige Phase III Studie erfolgreich laufen wird.
25.09.12 16:43
#97
Leo4Essen
Es sei hier noch auf einige Artikel bei
Seekingalpha verwiesen - alle von September 2012:
http://seekingalpha.com/article/...ed-case-for-pimavanserin-s-success
http://seekingalpha.com/article/...lass-next-generation-antipsychotic
27.11.12 22:10
#98
Heron
Positive Phase III Studie
ACADIA kündigt Pimavanserin Erfüllt Primary & Key Sekundäre Endpunkte in Phase III Parkinson Psychosis Tr ...
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) gab heute die erfolgreiche Top-Line-Ergebnisse aus der Phase-III-Studie zur Beurteilung der Wirksamkeit, Verträglichkeit und Sicherheit von pimavanserin bei Patienten mit Parkinson-Krankheit Psychose (PDP). Pimavanserin ist ACADIA proprietäre, nicht-dopaminergen Produktkandidaten, die selektiv blockiert Serotonin 5-HT 2A-Rezeptoren. Pimavanserin den primären Endpunkt in der Phase-III-Studie durch den Nachweis hochsignifikante antipsychotische Wirksamkeit, gemessen nach der 9-Punkt SAPS-PD-Skala (p = 0,001). Pimavanserin traf auch die wichtigen sekundären Endpunkt für motorische Verträglichkeit, gemessen unter Verwendung der Teile II und III der Unified Parkinson Disease Rating Scale oder UPDRS. Diese Ergebnisse wurden durch eine weitere sehr erhebliche Verbesserung der Wirksamkeit sekundären Maßnahme, die Clinical Global Impression Improvement, oder CGI-I, Skala (p = 0,001) unterstützt. Darüber hinaus wurden die klinischen Vorteile in allen explorativ die Wirksamkeit Maßnahmen mit signifikanten Verbesserungen in der Nacht schlafen, tagsüber wach und Pflegepersonal Belastung beobachtet. In Übereinstimmung mit früheren Studien war pimavanserin sicher und gut in dieser Phase-III-Studie gut vertragen.
http://www.reuters.com/article/2012/11/27/...hotStocksNews&rpc=43
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) gab heute die erfolgreiche Top-Line-Ergebnisse aus der Phase-III-Studie zur Beurteilung der Wirksamkeit, Verträglichkeit und Sicherheit von pimavanserin bei Patienten mit Parkinson-Krankheit Psychose (PDP). Pimavanserin ist ACADIA proprietäre, nicht-dopaminergen Produktkandidaten, die selektiv blockiert Serotonin 5-HT 2A-Rezeptoren. Pimavanserin den primären Endpunkt in der Phase-III-Studie durch den Nachweis hochsignifikante antipsychotische Wirksamkeit, gemessen nach der 9-Punkt SAPS-PD-Skala (p = 0,001). Pimavanserin traf auch die wichtigen sekundären Endpunkt für motorische Verträglichkeit, gemessen unter Verwendung der Teile II und III der Unified Parkinson Disease Rating Scale oder UPDRS. Diese Ergebnisse wurden durch eine weitere sehr erhebliche Verbesserung der Wirksamkeit sekundären Maßnahme, die Clinical Global Impression Improvement, oder CGI-I, Skala (p = 0,001) unterstützt. Darüber hinaus wurden die klinischen Vorteile in allen explorativ die Wirksamkeit Maßnahmen mit signifikanten Verbesserungen in der Nacht schlafen, tagsüber wach und Pflegepersonal Belastung beobachtet. In Übereinstimmung mit früheren Studien war pimavanserin sicher und gut in dieser Phase-III-Studie gut vertragen.
http://www.reuters.com/article/2012/11/27/...hotStocksNews&rpc=43